Diarrhea News and Research RSS Feed - Diarrhea News and Research

Diarrhea is loose, watery stools. A person with diarrhea typically passes stool more than three times a day. People with diarrhea may pass more than a quart of stool a day. Acute diarrhea is a common problem that usually lasts 1 or 2 days and goes away on its own without special treatment. Prolonged diarrhea persisting for more than 2 days may be a sign of a more serious problem and poses the risk of dehydration. Chronic diarrhea may be a feature of a chronic disease.

Diarrhea can cause dehydration, which means the body lacks enough fluid to function properly. Dehydration is particularly dangerous in children and older people, and it must be treated promptly to avoid serious health problems.
Researchers create new vaccine development method for H5N1, H7N9 strains of avian influenza

Researchers create new vaccine development method for H5N1, H7N9 strains of avian influenza

A recent study with Kansas State University researchers details vaccine development for two new strains of avian influenza that can be transmitted from poultry to humans. The strains have led to the culling of millions of commercial chickens and turkeys as well as the death of hundreds of people. [More]
New study suggests ways to accelerate recovery from dangerous diarrheal disease

New study suggests ways to accelerate recovery from dangerous diarrheal disease

A new study delineates a sequential pattern of changes in the intestinal microbial population of patients recovering from cholera in Bangladesh, findings that may point to ways of speeding recovery from the dangerous diarrheal disease. [More]
Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo. [More]
Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

Shionogi Inc. today announced data from a Phase IIb study that showed 0.2 mg and 0.4 mg of naldemedine demonstrated statistically significant efficacy in treating opioid-induced constipation (OIC) in patients with chronic non-cancer pain. [More]
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19. [More]

Commonwealth announces availability of new ELISA-based blood test to quickly and reliably diagnose IBS

Commonwealth Laboratories, Inc. announced today the availability of IBSchek, a new blood test designed to help physicians quickly and reliably diagnose Irritable Bowel Syndrome (IBS). [More]
Simple blood tests diagnose irritable bowel syndrome quickly and accurately

Simple blood tests diagnose irritable bowel syndrome quickly and accurately

Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist. [More]
Research finding could lead to better treatments for inflammatory bowel disease

Research finding could lead to better treatments for inflammatory bowel disease

Inflammatory bowel disease (IBD) afflicts 1.6 million people in the United States, causing abdominal pain, diarrhea, constipation, rectal bleeding and other potentially debilitating symptoms. [More]
Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015. [More]
Treatment significantly reduces risk of CDI recurrence

Treatment significantly reduces risk of CDI recurrence

Among patients with Clostridium difficile infection (CDI) who recovered following standard treatment with the antibiotics metronidazole or vancomycin, oral administration of spores of a strain of C difficile that does not produce toxins colonized the gastrointestinal tract and significantly reduced CDI recurrence, according to a study in the May 5 issue of JAMA. [More]
Fecal transplantation cures C. diff infection, eliminates multi-drug resistant pathogens

Fecal transplantation cures C. diff infection, eliminates multi-drug resistant pathogens

A fecal microbiota transplant (FMT) not only cured a case of Clostridium difficile (C. diff) infection in a 66 year old man; it eliminated populations of multi-drug resistant organisms both in the patient's gastrointestinal tract, and several other body sites. [More]
Relaxation response has significant impact on patients with gastrointestinal disorders

Relaxation response has significant impact on patients with gastrointestinal disorders

A pilot study has found that participating in a nine-week training program including elicitation of the relaxation response had a significant impact on clinical symptoms of the gastrointestinal disorders irritable bowel syndrome and inflammatory bowel disease and on the expression of genes related to inflammation and the body's response to stress. [More]
Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex Corporation today announced that testing at the clinical trial sites for the ARIES HSV 1&2 Assay is now complete. The next steps, including site to site reproducibility testing, followed by data analysis and assembly of the data package for submission to the FDA, are now underway. [More]
Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. [More]
U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Nearly half of American hospitals aren't taking key steps to prevent a kind of gut infection that kills nearly 30,000 people annually and sickens hundreds of thousands more - despite strong evidence that such steps work, according to a new study. [More]
Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis plc today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA). [More]
Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. [More]
Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. [More]

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP). [More]
Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS). [More]
Advertisement